EUVIMEDEUVIMED entdecken
Crossref

Polymeric nanoparticles containing 4-methoxychalcone attenuates hyperglycemia in diabetes-induced mice

Leonard Acho, Serafim Neto, Angela Maria Barros, Rosivaldo Borges, Breno N. Matos, Tatiane de Souza, Guilherme Gelfuso, Jesús Rafael Amado, Morteza Golbashirzadeh, Emersom Lima

Nanomedicine Journal · 2026-01 · 13 (1) · 159-169

DOI: 10.22038/nmj.2025.89217.2260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Journal, 2026-01. Verfasst von Leonard Acho und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective(s): Diabetes mellitus is a chronic metabolic disorder characterized by persistent disturbances in glucose homeostasis. Novel therapeutic strategies are needed to improve glycemic control while minimizing toxicity. This study investigated the hypoglycemic potential of 4‑methoxychalcone (MPP), synthesized via the Claisen–Schmidt reaction, and evaluated the efficacy of its nanoencapsulation in diabetic mice.

Methods

MPP was synthesized and subsequently nanoencapsulated (NCs) using ethanol, isopropyl palmitate, and organic phase surfactants. Nanocarriers were characterized by particle size, polydispersity index (PDI), zeta potential, and morphology through transmission electron microscopy (TEM). Diabetes was induced in CL57/6BL mice using streptozotocin/nicotinamide. Animals were treated for 28 days with free MPP (200 mg/kg), metformin (200 mg/kg), or NCs (10 mg/kg). Biochemical assays were performed on blood samples, and histological analyses were conducted on liver tissues.

Results

NCs exhibited a mean particle size of 187 nm, zeta potential of −19.9 mV, and PDI of 0.21, demonstrating stability across varying temperatures and pH conditions. TEM confirmed spherical morphology and uniform distribution. Both metformin (176.33 ± 44.68 mg/dL, p < 0.0001) and NCs (163.2 ± 76.3 mg/dL, p < 0.0001) significantly reduced blood glucose levels. NCs further normalized glycated hemoglobin (HbA1c) without evidence of hepatotoxicity, as indicated by low malondialdehyde levels and preserved liver histology.

Conclusion

Nanoencapsulation of MPP enhances its antidiabetic efficacy, enabling therapeutic effects at lower doses while reducing toxicity risks. This strategy represents a promising approach for the development of safer and more effective antidiabetic interventions.

Schlagwörter

diabetes mellitusglycated hemoglobinhypoglycemic agentsmicenanocapsules

Zitieren

APA

Acho, L., Neto, S., Barros, A. M., Borges, R., Matos, B. N., Souza, T. D., Gelfuso, G., Amado, J. R., Golbashirzadeh, M., & Lima, E. (2026). Polymeric nanoparticles containing 4-methoxychalcone attenuates hyperglycemia in diabetes-induced mice. Nanomedicine Journal, 13(1), 159-169. https://doi.org/10.22038/nmj.2025.89217.2260

Vancouver

Acho L, Neto S, Barros AM, Borges R, Matos BN, Souza TD, et al. Polymeric nanoparticles containing 4-methoxychalcone attenuates hyperglycemia in diabetes-induced mice. Nanomedicine Journal. 2026;13(1):159-169. doi:10.22038/nmj.2025.89217.2260

BibTeX
@article{Acho2026,
  author = {Acho, Leonard and Neto, Serafim and Barros, Angela Maria and Borges, Rosivaldo and Matos, Breno N. and Souza, Tatiane de and Gelfuso, Guilherme and Amado, Jesús Rafael and Golbashirzadeh, Morteza and Lima, Emersom},
  title = {Polymeric nanoparticles containing 4-methoxychalcone attenuates hyperglycemia in diabetes-induced mice},
  journal = {Nanomedicine Journal},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {159--169},
  doi = {10.22038/nmj.2025.89217.2260}
}
Kostenlos starten →